Johnson & Johnson/$JNJ

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Ticker

$JNJ
Sector
Health

Primary listing

NYSE

Employees

138,100
Headquarters
New Brunswick, United States
Website
www.jnj.com

JNJ Metrics

BasicAdvanced
$460B
18.44
$10.35
-
$5.08
2.72%

What the Analysts think about JNJ

Analyst ratings (Buy, Hold, Sell) for Johnson & Johnson stock.

Bulls say / Bears say

J&J beat Q2 2025 profit estimates with adjusted EPS of $2.77 (vs. $2.68 expected), driven by Darzalex oncology sales of $3.54 billion and a 6.1% medtech revenue increase, leading to full‐year sales guidance raised to $93.2–93.6 billion (Reuters)
The FDA approved Imaavy for generalized myasthenia gravis on April 30, 2025, covering over 90% of U.S. patients and targeting peak annual sales above $5 billion, bolstering J&J’s immunology portfolio (Reuters)
On September 9, 2025, the FDA approved Inlexzo (TAR-200) for high‐risk non–muscle invasive bladder cancer, demonstrating over 82% patient response at three months and providing a non‐surgical treatment for ~75% of bladder cancer cases (Reuters)
A U.S. judge rejected J&J’s $10 billion proposal to settle talc litigation on April 1, 2025, forcing the company to defend against over 60,000 claims in court and prolonging legal uncertainty (Reuters)
A July 29, 2025 Massachusetts jury awarded $42.6 million to a mesothelioma plaintiff who alleged J&J’s talc contained asbestos, highlighting ongoing exposure to large punitive verdicts across 63,000+ talc suits (Reuters)
J&J is under a federal criminal investigation over its disclosures about talc safety, adding a layer of regulatory risk and potential penalties to its prolonged litigation saga (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.

JNJ Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

JNJ Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

JNJ News

AllArticlesVideos
These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings

These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings

Benzinga4 hours ago
Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

Benzinga4 hours ago
Johnson & Johnson's MedTech spin-off could boost focus, Bank of America says

Johnson & Johnson's MedTech spin-off could boost focus, Bank of America says

Proactive Investors5 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $JNJ

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

FAQs